Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, Barbash GI, Hampton JR, Guerci A, Simes RJ, et al. Van de Werf F, et al. Among authors: guerci a. JAMA. 1995 May 24-31;273(20):1586-91. doi: 10.1001/jama.273.20.1586. JAMA. 1995. PMID: 7745771 Clinical Trial.
Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial.
Newby LK, Califf RM, Guerci A, Weaver WD, Col J, Horgan JH, Mark DB, Stebbins A, Van de Werf F, Gore JM, Topol EJ. Newby LK, et al. Among authors: guerci a. J Am Coll Cardiol. 1996 Mar 1;27(3):625-32. doi: 10.1016/0735-1097(95)00513-7. J Am Coll Cardiol. 1996. PMID: 8606274 Free article.
Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries.
Betriu A, Califf RM, Bosch X, Guerci A, Stebbins AL, Barbagelata NA, Aylward PE, Vahanian A, Van de Werf F, Topol EJ. Betriu A, et al. Among authors: guerci a. J Am Coll Cardiol. 1998 Jan;31(1):94-102. doi: 10.1016/s0735-1097(97)00428-2. J Am Coll Cardiol. 1998. PMID: 9426024 Free article.
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
Greenbaum AB, Harrington RA, Hudson MP, MacAulay CM, Wilcox RG, Simoons ML, Berdan LG, Guerci A, Cokkinos DV, Kitt MM, Lincoff AM, Topol EJ, Califf RM, Ohman EM. Greenbaum AB, et al. Among authors: guerci a. J Am Coll Cardiol. 2001 Feb;37(2):492-8. doi: 10.1016/s0735-1097(00)01143-8. J Am Coll Cardiol. 2001. PMID: 11216968 Free article. Clinical Trial.
Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, Guerci AD, Vahanian A, Califf RM, Ohman EM. Hudson MP, et al. Among authors: guerci ad. Circulation. 2001 Sep 11;104(11):1229-35. doi: 10.1161/hc3601.095717. Circulation. 2001. PMID: 11551872
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM, Pepine CJ, Kopecky SL, Kleiman NS, Pacchiana CM, Berdan LG, Kitt MM, Simoons ML, Topol EJ. Lincoff AM, et al. Among authors: guerci ad. Circulation. 2000 Sep 5;102(10):1093-100. doi: 10.1161/01.cir.102.10.1093. Circulation. 2000. PMID: 10973836 Clinical Trial.
231 results